Information Provided By: 
Fly News Breaks for April 18, 2018
RIGL
Apr 18, 2018 | 08:21 EDT
Jefferies analyst Eun Yang raised her price target for Rigel Pharmaceuticals to $7 saying the approval of Tavalisse is a transformational event for the company. The analyst views the label as "clean" and has a peak sales estimate of $190M in chronic immune thrombocytopenia. She believes the additional opportunity for second indication autoimmune hemolytic anemia will likely be a further driver of valuation. Yang keeps a Buy rating on Rigel.
News For RIGL From the Last 2 Days
There are no results for your query RIGL
